Diamonds in the Rough: Protein Crystals from a Formulation Perspective

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2002 Jan 5

PMID 11758753

Citations 7

Authors

A Jen

H P Merkle

Affiliations

Soon will be listed here.

Abstract

The focus of the present review is to address the use of protein crystals in formulation design. Although this idea has been present for some time, i.e., insulin crystals were first reported back in 1920s, macromolecular crystallization has not received as much attention as the other methods for stabilizing protein drug candidates. The prospective potential of crystalline protein formulations in light of new advances in the field of macromolecular crystallization was reviewed, and the basic concepts and the tools now available for developing protein crystals into drug formulations are introduced. In addition, formulation challenges and regulatory demands, along with examples of current applications of protein crystals, are presented.

Citing Articles

Polymorphic nanobody crystals as long-acting intravitreal therapy for wet age-related macular degeneration.

Zhu S, Fan S, Tang T, Huang J, Zhou H, Huang C Bioeng Transl Med. 2023; 8(6):e10523.

PMID: 38023710 PMC: 10658565. DOI: 10.1002/btm2.10523.

Structural principles of insulin formulation and analog design: A century of innovation.

Jarosinski M, Dhayalan B, Chen Y, Chatterjee D, Varas N, Weiss M Mol Metab. 2021; 52:101325.

PMID: 34428558 PMC: 8513154. DOI: 10.1016/j.molmet.2021.101325.

Metal ions guided self-assembly of therapeutic proteins for controllable release: from random to ordered aggregation.

Shi K, Cui F, Bi H, Jiang Y, Shi H, Song T Pharm Res. 2012; 30(1):269-79.

PMID: 22975806 DOI: 10.1007/s11095-012-0871-9.

Crystal polymorphism of protein GB1 examined by solid-state NMR spectroscopy and X-ray diffraction.

Frericks Schmidt H, Sperling L, Gao Y, Wylie B, Boettcher J, Wilson S J Phys Chem B. 2007; 111(51):14362-9.

PMID: 18052145 PMC: 2774121. DOI: 10.1021/jp075531p.

Novel long-acting crystal formulation of human growth hormone.

Govardhan C, Khalaf N, Jung C, Simeone B, Higbie A, Qu S Pharm Res. 2005; 22(9):1461-70.

PMID: 16132358 DOI: 10.1007/s11095-005-6021-x.

References

Stura E, Satterthwait A, Calvo J, Kaslow D, Wilson I . Reverse screening. Acta Crystallogr D Biol Crystallogr. 1994; 50(Pt 4):448-55. DOI: 10.1107/S0907444994001794. View

Lee , Vaghjiani , Lye , Turner . A systematic approach to the large-scale production of protein crystals. Enzyme Microb Technol. 2000; 26(8):582-592. DOI: 10.1016/s0141-0229(99)00194-5. View

Frey M . Water structure associated with proteins and its role in crystallization. Acta Crystallogr D Biol Crystallogr. 1994; 50(Pt 4):663-6. DOI: 10.1107/S0907444993013368. View

Wiencek J . New strategies for protein crystal growth. Annu Rev Biomed Eng. 2001; 1:505-34. DOI: 10.1146/annurev.bioeng.1.1.505. View

Govardhan C . Crosslinking of enzymes for improved stability and performance. Curr Opin Biotechnol. 1999; 10(4):331-5. DOI: 10.1016/S0958-1669(99)80060-3. View

Hildebrandt P, Berger A, Volund A, Kuhl C . The subcutaneous absorption of human and bovine ultralente insulin formulations. Diabet Med. 1985; 2(5):355-9. DOI: 10.1111/j.1464-5491.1985.tb00650.x. View

Byrn S, Pfeiffer R, Ganey M, Hoiberg C, Poochikian G . Pharmaceutical solids: a strategic approach to regulatory considerations. Pharm Res. 1995; 12(7):945-54. DOI: 10.1023/a:1016241927429. View

Qian C, Lagace L, Massariol M, Chabot C, Yoakim C, Deziel R . A rational approach towards successful crystallization and crystal treatment of human cytomegalovirus protease and its inhibitor complex. Acta Crystallogr D Biol Crystallogr. 2000; 56(Pt 2):175-80. DOI: 10.1107/s0907444999015103. View

Cudney R, Patel S, Weisgraber K, Newhouse Y, McPherson A . Screening and optimization strategies for macromolecular crystal growth. Acta Crystallogr D Biol Crystallogr. 1994; 50(Pt 4):414-23. DOI: 10.1107/S0907444994002660. View

10.

Vogl T, Hinz H . Characterization of recombinant proteins: biochemical and biophysical criteria for the identity of native and renatured human tissue plasminogen activator and its mutants. Biotechnol Appl Biochem. 1994; 20(1):1-22. View

11.

Putney S, Burke P . Improving protein therapeutics with sustained-release formulations. Nat Biotechnol. 1998; 16(2):153-7. DOI: 10.1038/nbt0298-153. View

12.

Margolin A, Navia M . Protein Crystals as Novel Catalytic Materials. Angew Chem Int Ed Engl. 2001; 40(12):2204-2222. DOI: 10.1002/1521-3773(20010618)40:12<2204::aid-anie2204>3.0.co;2-j. View

13.

Pikal M, Rigsbee D . The stability of insulin in crystalline and amorphous solids: observation of greater stability for the amorphous form. Pharm Res. 1997; 14(10):1379-87. DOI: 10.1023/a:1012164520429. View

14.

St Clair N, Shenoy B, Jacob L, Margolin A . Cross-linked protein crystals for vaccine delivery. Proc Natl Acad Sci U S A. 1999; 96(17):9469-74. PMC: 22232. DOI: 10.1073/pnas.96.17.9469. View

15.

Brange J, Langkjoer L . Insulin structure and stability. Pharm Biotechnol. 1993; 5:315-50. DOI: 10.1007/978-1-4899-1236-7_11. View

16.

McPherson A . Current approaches to macromolecular crystallization. Eur J Biochem. 1990; 189(1):1-23. DOI: 10.1111/j.1432-1033.1990.tb15454.x. View

17.

Mittl P, Priestle J, Cox D, McMaster G, Cerletti N, Grutter M . The crystal structure of TGF-beta 3 and comparison to TGF-beta 2: implications for receptor binding. Protein Sci. 1996; 5(7):1261-71. PMC: 2143453. DOI: 10.1002/pro.5560050705. View

18.

Brange J, Langkjaer L . Insulin formulation and delivery. Pharm Biotechnol. 1997; 10:343-409. DOI: 10.1007/0-306-46803-4_13. View

19.

Perrakis A, Cipriani F, Castagna J, Claustre L, Burghammer M, Riekel C . Protein microcrystals and the design of a microdiffractometer: current experience and plans at EMBL and ESRF/ID13. Acta Crystallogr D Biol Crystallogr. 1999; 55(Pt 10):1765-70. DOI: 10.1107/s0907444999009348. View

20.

Stevens R . High-throughput protein crystallization. Curr Opin Struct Biol. 2000; 10(5):558-63. DOI: 10.1016/s0959-440x(00)00131-7. View